|Bid||0.00 x 900|
|Ask||0.00 x 1000|
|Day's Range||47.32 - 48.51|
|52 Week Range||38.00 - 72.96|
|Beta (3Y Monthly)||1.29|
|PE Ratio (TTM)||24.71|
|Earnings Date||Feb 26, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||55.43|
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Small-caps and large-caps are wildly popular amongRead More...
ALPHARETTA, Ga., Feb. 12, 2019 /PRNewswire/ -- Avanos Medical, Inc. (AVNS) will webcast its conference call discussing financial results and business highlights for the fourth quarter and full-year 2018 and its 2019 outlook on Tuesday, Feb. 26 at 9 a.m. ET. The conference call will be hosted by Joe Woody, chief executive officer, and Steve Voskuil, senior vice president and chief financial officer. To join the live conference call, dial 877-240-5772 in the United States.
Avanos Medical Inc NYSE:AVNSView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is moderate * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NeutralShort interest is moderate for AVNS with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding AVNS totaled $425 million. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
ALPHARETTA, Ga. , Jan. 3, 2019 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today announced that Joe Woody , chief executive officer, will present at the 37 th Annual J.P. Morgan Healthcare Conference ...
Reputable billionaire investors such as Nelson Peltz and David Tepper generate exorbitant profits for their wealthy accredited investors (a minimum of $1 million in investable assets would be required to invest in a hedge fund and most successful hedge funds won’t accept your savings unless you commit at least $5 million) by pinpointing winning small-cap […]
ALPHARETTA, Ga. , Dec. 17, 2018 /PRNewswire/ -- Avanos Medical, Inc. today announced that David Ball has been appointed senior vice president, global supply chain & procurement. In this role, Ball will ...
ALPHARETTA, Ga., Dec. 10, 2018 /PRNewswire/ -- Avanos Medical, Inc. (AVNS) is pleased to announce it has been selected as one of eight winners of the FDA's Opioid Addiction Innovation Challenge. The FDA launched the challenge in May 2018 to spur the development of medical devices and solutions to help combat the growing epidemic of opioid misuse and abuse. Avanos was selected as one of eight winners among more than 250 submissions from medical device companies and/or developers.
CEO of Avanos Medical Inc (NYSE:AVNS) Joseph Fralin Woody bought 3,500 shares of AVNS on 11/28/2018 at an average price of $43.35 a share.
Data from Avanos Medical offers guidance to understanding long-term pain relief seen in cooled radiofrequency versus standard techniques. ALPHARETTA, Ga. , Nov. 16, 2018 /PRNewswire/ -- Avanos Medical, ...
Avanos Medical (AVNS) delivered earnings and revenue surprises of 27.59% and -0.60%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
ALPHARETTA, Ga. , Nov. 6, 2018 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today reported third quarter 2018 results and affirmed its full-year 2018 adjusted diluted earnings per share outlook of ...
ALPHARETTA, Ga. , Nov. 5, 2018 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today announced that Joe Woody , chief executive officer, will present at the Stifel 2018 Healthcare Conference at The Lotte ...
ALPHARETTA, Ga. , Oct. 23, 2018 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) will webcast its conference call discussing financial results and business highlights for the third quarter 2018 on Tuesday, ...
ALPHARETTA, Ga. , Sept. 6, 2018 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today announced that Steve Voskuil , chief financial officer, will present at the Morgan Stanley Global Healthcare Conference ...
Stocks with market capitalization between $2B and $10B, such as Avanos Medical Inc (NYSE:AVNS) with a size of US$2.69b, do not attract as much attention from the investing community asRead More...